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Abstract
Background: More than 75% of patients presenting to the Emergency Department are suffering symptoms of pain.
Despite this, 67% will not receive any analgesia. Methoxyflurane is a fluorinated hydrocarbon gas which has
analgesic properties when inhaled. Penthrox is a methoxyflurane autoinhaler recently licenced in Europe. Its ease of
administration, safety, and fast onset of action make it of particular relevance to emergency medicine. Additionally,
outside the hospital, it has the advantage of increased temperature stability and portability over current standard
care. New evidence of its efficacy is emerging; however, currently, its use in Europe is not widespread. The
objective of this study will be to systematically evaluate the evidence on inhaled methoxyflurane to determine if it
is a superior analgesia in the acute trauma setting.
Methods: We designed and registered a study protocol for a systematic review and meta-analysis on randomised
controlled trials, comparing inhaled methoxyflurane and either placebo or standard care. A comprehensive search
will be conducted from database inception onwards in MEDLINE, Embase, and the Cochrane CENTRAL database,
concurrent with a search of the grey literature for other relevant studies, including clinical trial databases. Only
randomised controlled trials will be included. No limitations will be imposed on publication status or language of
publication. The primary outcome will be mean difference in patient-reported pain at time points within the first
30 min of administration. Secondary outcomes will be mean difference in time to clinically significant pain relief
and relative risk of adverse effects. Two reviewers will independently screen all returned studies and collect data.
Disagreements will be resolved through discussion or referral to a third reviewer. Individual study methodological
quality will be appraised using an appropriate tool. If feasible, we will conduct a random effects meta-analysis; if this
is not possible, we will construct a narrative synthesis.
Discussion: This systematic review will summarise the best available evidence and definitively establish if inhaled
methoxyflurane is a superior analgesia to standard care in the acute trauma setting. This knowledge will directly
impact emergency care in the UK and worldwide and may require amendments to European pain relief guidelines.
Systematic review registration: PROSPERO CRD42020189119.
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Background
Methoxyflurane (the active ingredient in Penthrox) is a
fluorinated hydrocarbon initially licensed as an inhaled
anaesthetic agent in 1962 before reports of nephrotox-
icity caused it to fall out of favour in the late 1970s; it
was voluntarily removed from the market in 2001 [1–3].
However, at lower doses, it has properties as an anal-
gesic and a self-administered methoxyflurane inhalator
was marketed as the Analgizer in the 1970s. Whilst the
Analgizer itself was withdrawn, methoxyflurane autoin-
halers have been extensively used in Australia since
1975, are first line for moderate-to-severe analgesia in
several Australian ambulance services [1], and are rec-
ommended by the Australian and New Zealand College
of Anaesthetists pain management guidelines [4]. It has
come into vogue in Europe relatively recently following
the licencing of Penthrox, a methoxyflurane autoinhaler
marketed in Europe by Mundipharma and in the UK by
Galen [5]. As a result, there have been several large stud-
ies performed in the last 6 years [6–9]. Along with most
anaesthetics, the mechanism of action of methoxyflurane
is unclear [10].
Proponents of inhaled methoxyflurane argue that it
could help minimise oligoanalgesia in the emergency de-
partment due to fewer barriers to administration com-
pared to other medications available such as nitrous
oxide, opioids, or ketamine [1, 11]. This is particularly
significant as pain makes up 75–80% of all emergency
department attendances [12] and yet in large-scale Euro-
pean studies two thirds of patients presenting with pain
do not receive any analgesia [13, 14].
Other studies suggest methoxyflurane provides quicker
onset of pain relief than current standard of care given
the same time of provision [7, 8]. There is also evidence
that it could provide a more stable, safe, and easy form
of pain relief in austere or pre-hospital environments
[15].
Critics have cautioned that it does not provide enough
benefit over normal practice to justify its uptake [16].
There are concerns regarding potential occupational
health risk to healthcare workers (particularly in the
enclosed spaces found in the pre-hospital environment)
[17], although this risk mitigated with the addition of an
activated charcoal filter [11, 18]. Historically, there were
concerns that nephrotoxicity seen at anaesthetic doses
might be seen at analgesic doses, although this does not
appear to be true [3].
Alternatives to inhaled methoxyflurane are morphine
and Entonox (inhaled nitrous oxide) [11]. Morphine is
considered the gold-standard for pain relief but can
cause dependency and requires monitoring due to re-
spiratory depression. Furthermore, the evidence suggests
this leads to low starting doses and long periods of inad-
equate analgesia [12, 19]. Entonox equipment is bulky
which delays its administration in the emergency depart-
ment [11] and makes it impractical pre-hospital [15, 20].
The aim of this study will be to systematically evaluate
the evidence and determine if inhaled methoxyflurane is
a superior analgesia to standard care in the acute trauma
setting.
Methods
This protocol has been registered with PROSPERO
international prospective register of systematic reviews
(registration number CRD42020189119) and has been
reported in accordance with the Preferred Reporting
Items for Systematic Reviews and Meta-Analysis Proto-
cols (PRISMA-P) 2015 statement [21]. The PRISMA-P
checklist for this study is included in Additional file 1.
The methodology of this review will be according to the
Cochrane Handbook for Systematic Review of Interven-
tions [22]. The final review will be reported following
the PRISMA statement [23]. Should any changes to the
protocol prove necessary these will be included in the
final publication and updated on PROSPERO detailing
the nature of the change, the date, and the rationale.
Information sources and search strategy
The primary sources will be a structured search from in-
ception onwards of major electronic databases: MEDL
INE, Embase, and the Cochrane CENTRAL database.
We will further search the grey literature for other pos-
sible relevant studies, including OpenGrey and clinical
trial databases (ClinicalTrials.gov, ISRCTN registry, clin-
icaltrialsregister.eu, and Australian and New Zealand
Clinical Trials Registry). We will perform hand-searches
of reference lists of included studies. The literature
searches will be designed and conducted by the review
team which includes two experienced health information
specialists. The search will be performed in English and
any relevant non-English articles will be translated.
The search will include a broad range of terms and
keywords related to methoxyflurane, Penthrox, trauma,
pain, and study design (based on the Cochrane Hand-
book randomised controlled trials [RCT] search guide-
line) [22]. The search strategy for MEDLINE is included
as Additional File 2.
Study selection
After removing duplicates, search results will be
screened by two reviewers independently using titles and
abstracts against pre-specified inclusion and exclusion
criteria. All included articles at this point will the
undergo a full text review and the data will be extracted.
This will again be performed independently by two re-
viewers. Any discordance at any stage will be resolved
through discussion or referral to a third reviewer if re-
quired. The screening process will be performed in
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Rayann [24], a web-based application for systematic re-
view. The reason for exclusion of records will be re-
corded at each stage. Records will be kept of each stage
and a PRISMA flow-chart published with the review.
Eligibility criteria
Studies will be included or excluded based on the fol-
lowing criteria, sub-divided into population, interven-
tion, comparator, outcome measures, and study design.
We will not exclude based on publication status, lan-
guage, or date of publication.
Participants/population
We will include clinical trials on patients of all ages with
traumatic pain within the acute setting—specifically the
pre-hospital environment (including transport) and the
emergency department. We will exclude studies utilising
methoxyflurane for procedural or obstetric analgesia.
Interventions
In order to maintain relevance to the newly licensed
Penthrox autoinhaler, we will include only studies which
offer self-administered methoxyflurane at doses similar
to those Penthrox is currently licenced for (3 ml/h and
max 6ml/day, or 0.59 MAC-hours [minimum alveolar
concentration hours]) [25]. We will exclude any studies
using doses above 2.0 MAC-hours, the level at which
nephrotoxicity has been reported in humans [3].
Comparators
It has been reported there has previously been a paucity
of controlled studies on methoxyflurane using active
comparators [20]. As a result we will include studies
using all comparators, including placebo with rescue
medications.
Outcome measures
The primary outcome will be mean difference in
patient-reported pain relief using any validated pain
scale (such as visual analogue scale [VAS] or visual nu-
merical rating scale [VNRS]) from time of administra-
tion up to 30min after. The secondary outcomes will be
mean difference in time to first clinically significant pain
relief from time of administration and relative risk of ad-
verse events.
Study designs
We will only include RCTs. We will exclude non-
randomised trials including cohort studies, letters, re-
views, cases series, case reports, and subgroup analyses
of other studies.
Settings
Studies will be included if they take place in the emer-
gency department or in the pre-hospital setting. Studies
taking place outside of this, such as in theatre, will be
excluded.
Data extraction
All full-text articles identified as appropriate for the re-
view will have their data extracted independently and in
duplicate by two reviewers using a standardised data ex-
traction sheet with the following headings:
1. Study characteristics
(a) Lead author, year, title, study design, blinding,
and pain scale used
(b) Population
I Country of study, location, and inclusion
and exclusion criteria
(c) Intervention dose and frequency
(d) Comparator including definition of standard of
care if included
(e) Primary and secondary study outcomes
Results
(f) Number screened, number included, number of
drop outs, and length of follow up
(g) Demographics (number, age, and gender of control
and treatment arms, mean and standard deviation
of each where appropriate)
(h) Mean/median and standard deviation of pain scores
in control and treatment arm at baseline and at 5,
10, 15, 20, and 30 min, as well as any other times
added
(i) Mean time to reported pain relief in control and
treatment arm if recorded including confidence
intervals
(j) Adverse effects recorded in control and treatment
arm
In the event of missing data, we will contact the au-
thors via email to request access to their data as this has
the highest rate of response [26]. As evidence shows that
30% of authors are uncontactable [27] and that repeated
attempts to contact them do not increase success [26],
we will only attempt to contact authors once. If full data
is not obtainable, studies with partial data will be in-
cluded in the synthesis if appropriate and missing data
will be imputed from reported outcomes as possible in
line with the Cochrane handbook [22].
Assessment of risk of bias of included studies
We will use the Cochrane RoB (Risk of Bias) 2 tool [28]
to assess risk of bias for individual RCTs. They will be
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scored independently and in duplicate with any disagree-
ments being resolved through discussion and referral of
a third independent review if required. The results of the
risk of bias tool will be used in a sensitivity analysis to
ensure studies judged to be at ‘high’ risk of bias do not
affect the robustness of our results in any subsequent
meta-analysis.
Data analysis
To address the main review question, data will be syn-
thesised to establish whether methoxyflurane is superior
to standard care for analgesia in acute trauma. The data
from included study will be used to build evidence tables
for an overall description of included studies for me-
thoxyflurane in the trauma setting. This will include
study characteristics, context, participants, outcomes,
and findings. If the same pain scales have been used,
then we will calculate the mean difference with 95% con-
fidence intervals of inhaled methoxyflurane vs standard
care/placebo. In the event that different scales have been
used we will calculate standardised mean difference with
95% confidence intervals. The results of this will be pre-
sented in a forest plot. This will be undertaken in Rev-
Man [29].
To determine the extent of variation between selected
studies, tests of heterogeneity will be performed. Inter-
study heterogeneity will be assessed visually using the
forest plot. Statistical heterogeneity will be quantified
statistically using three tests. The I2 statistic will be used
and the result will be interpreted using the definitions in
the Cochrane Handbook for Systematic Reviews of In-
terventions [22]. Additionally, the Chi2 and Tau2 statistic
will be used where a p value < 0.10 will be deemed as
statistically significant for heterogeneity. Any sources of
heterogeneity will be explored using subgroup analysis.
If two or more comparative studies with an absence of
clinical heterogeneity are identified by the systematic re-
view, then we will perform a random effects meta-
analysis. This approach is appropriate given it is likely
that the true effect size varies from study to study and
these follow a normal distribution.
Additional analysis
If sufficient studies are identified and data points are
available, potential sources of heterogeneity will be in-
vestigated further by subgroup or meta-regression ana-
lyses. We plan to conduct analysis to establish the
relative risk of adverse events presented in the trials.
Subgroup analysis will be considered on trials vs placebo
with rescue medicine and trials vs active comparators.
We will use the grading of recommendations assess-
ment, development, and evaluation (GRADE) working
group methodology [30] to assess our confidence in the
cumulative evidence and will include a full explanation
of our rationale. If quantitative synthesis is not appropri-
ate for any reason (e.g. clinical heterogeneity) a narrative
synthesis undertaken according to synthesis without
meta-analysis (SWiM) guidelines [31].
Sensitivity analysis will be performed on any studies
with imputed values and studies judged to be at high
risk of bias to ensure the robustness of our results.
Meta-biases
If there are 10 or more studies with the same outcome,
publication bias will be assessed by inspecting a funnel
plot for asymmetry and, if appropriate, using Egger’s test
[32].
Discussion
Pain as a symptom is both ubiquitous and difficult to
manage, particularly early in the patient care pathway
when other considerations can seem more pressing.
Early effective pain relief is something we owe our pa-
tients but with limited time it is important that we are
confident in the evidence base behind our decisions, par-
ticularly when considering a change in practice. This
systematic review protocol presents the method to iden-
tify and synthesise the highest quality of evidence re-
garding the level of pain relief provided by inhaled
methoxyflurane in traumatic pain in comparison to
current practice, the first to do so since the publication
of the recent European RCTs. This in turn will help in-
form the discussion on the more widespread introduc-
tion of methoxyflurane autoinhalers into current
practice in Europe.
One of the main issues anticipated with this study is
the difficulty in defining a clinically significant—as op-
posed to a statistically significant—change in a patient-
reported pain scale. The literature is significantly divided
on this and it is unclear whether absolute or relative
changes are more valuable to patients. The absolute
values proposed range from 8 to 40 mm on the VAS
scale [33]. A commonly cited number for clinical signifi-
cance is 13 mm [8, 15, 20], although this is disputed and
some argue that a higher threshold should be used when
considering a change in practice to decrease the chance
of a clinical reversal [34]. However, for the purposes of
ascertaining first clinically significant pain relief we will
use 13 mm with the understanding that this is based on
consensus rather than a clear clinical cut off.
There are some other potential limitations anticipated,
particularly the paucity of higher levels of evidence com-
paring inhaled methoxyflurane with active comparators
as previously identified [35]. We hope that the recently
published European studies will rectify this short fall.
We also anticipate a significant proportion of included
studies will be industry sponsored which a Cochrane re-
view found to increase the degree of efficacy of a new
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medication [36]. If this is the case, we will identify and
discuss this in the review publication.
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s13643-021-01600-0.
Additional file 1:. PRISMA-P Checklist
Additional file 2:. MEDLINE search strategy
Abbreviations
Embase: Excerpta Medica Database; GRADE: Grading of recommendations
assessment, development, and evaluation; MAC: Minimum alveolar
concentration; PRISMA: Preferred reporting items for systematic reviews and
meta-analysis; PRISMA-P: Preferred reporting items for systematic reviews and
meta-analysis protocols; RCT: Randomised controlled trial; RoB: Risk of bias;
SoC: Standard of care; SWiM: Synthesis without meta-analysis; UK: United
Kingdom of Great Britain and Northern Ireland; VAS: Visual analogue scale;




ME and KT devised the initial research question. ME and GN created the
study design. All authors read and approved the final manuscript.
Funding
No external sources of funding. No one other than the stated authors had
any input to the study design, data collection and analysis, or the text of the
publication.
Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated
or analysed during the current protocol.





The authors declare no competing interests.
Author details
1Academic Department of Military General Practice & Primary Care, Research
and Clinical Innovation, Royal Centre for Defence Medicine, HQ Joint Medical
Group, ICT Centre, Vincent Drive, Edgbaston, Birmingham B15 2SQ, UK.
2Department of Anaesthetics and Critical Care, Queen Elizabeth Hospital,
University Hospitals Birmingham NHS Trust, Mindelsohn Way, Edgbaston B15
2TH, UK. 3Division of Surgery & Interventional Science, University College
London, Royal Free Hospital, Pond Street, London NW3 2QG, UK.
4Department of Plastic and Reconstructive Surgery, Whiston Hospital, St.
Helens and Knowsley Teaching Hospitals NHS Trust, Warrington Road,
Prescot, Merseyside L35 5DR, UK.
Received: 2 September 2020 Accepted: 26 January 2021
References
1. Porter KM, Dayan AD, Dickerson S, Middleton PM. The role of inhaled
methoxyflurane in acute pain management. Open Access Emerg Med. 2018;
10:149–64. https://doi.org/10.2147/OAEM.S181222.
2. Raja SN, Mazze RI. Methoxyflurane revisited: tale of an anesthetic from
cradle to grave. Anethesiology. 2006;105:843–6.
3. Dayan AD. Analgesic use of inhaled methoxyflurane. Hum Exp Toxicol. 2016;
35(1):91–100. https://doi.org/10.1177/0960327115578743.
4. Schug SA, Palmer GM, Scott DA, Halliwell R, Trinca J, eds. Acute pain
management: scientific evidence. Fourth Edi. Australian and New Zealand
College of Anaesthetists and Faculty of Pain Medicine; 2015. www.tga.gov.au
5. Introducing Penthrox® | Penthrox Europe – Methoxyflourane. Accessed June
1, 2020. https://www.penthrox.eu/intro/
6. Coffey F, Wright J, Hartshorn S. STOP!: a randomised, double-blind, placebo-
controlled study of the efficacy and safety of methoxyflurane for the
treatment of acute pain. Emerg Med J. Published online 2014. doi:https://
doi.org/10.1136/emermed-2014-203690
7. Borobia AM, Collado SG, Cardona CC, et al. Inhaled methoxyflurane provides
greater analgesia and faster onset of action versus standard analgesia in
patients with trauma pain: InMEDIATE: a randomized controlled trial in
emergency departments. Ann Emerg Med. 2020;75(3):315–28. https://doi.
org/10.1016/j.annemergmed.2019.07.028.
8. Mercadante S, Voza A, Serra S, et al. Analgesic efficacy, practicality and
safety of inhaled methoxyflurane versus standard analgesic treatment for
acute trauma pain in the emergency setting: a randomised, open-label,
active-controlled, multicentre trial in Italy (MEDITA). Adv Ther. 2019;36(11):
3030–46. https://doi.org/10.1007/s12325-019-01055-9.
9. Ricard-Hibon A, Lecoules N, Savary D, et al. Inhaled methoxyflurane for the
management of trauma related pain in patients admitted to hospital
emergency departments (PenASAP study). Eur J Emerg Med Published
online April 2020:1. doi:https://doi.org/10.1097/mej.0000000000000686
10. Forrest M, Porter K, van der Velde J. Methoxyflurane (Penthrox®)—a case
series of use in the prehospital setting. J Paramedic Practice. 2019;11(2):54–
60. https://doi.org/10.12968/jpar.2019.11.2.54.
11. Frangos J, Belbachir A, Dautheville S, et al. Non-interventional study
evaluating exposure to inhaled, low-dose methoxyflurane experienced by
hospital emergency department personnel in France. BMJ Open. 2020;10(2):
e034647. https://doi.org/10.1136/bmjopen-2019-034647.
12. Cisewski DH, Motov SM. Essential pharmacologic options for acute pain
management in the emergency setting. Turk J Emerg Med. 2019;19(1):1–11.
https://doi.org/10.1016/j.tjem.2018.11.003.
13. Dale J, Bjørnsen LP. Assessment of pain in a Norwegian Emergency
Department. Scand J Trauma, Resusc Emerg Med. 2015;23(1):86. https://doi.
org/10.1186/s13049-015-0166-3.
14. Mura P, Serra E, Marinangeli F, et al. Prospective study on prevalence,
intensity, type, and therapy of acute pain in a second-level urban
emergency department. J Pain Res. 2017;10:2781–8. https://doi.org/10.2147/
JPR.S137992.
15. Cohen HML, Wolstenholme R. Penthrox: a breath of PHEC air for the
military? J R Army Med Corps Month. 2019;0(0). https://doi.org/10.1136/
jramc-2018-001122.
16. Montassier E, Freund Y. A rigorous evaluation of methoxyflurane is needed:
comment on “Methoxyflurane versus standard of care for acute trauma-
related pain in the emergency setting: protocol for a randomised,
controlled study in Italy (MEDITA)”. Adv Ther. 2019;36(6):1241. https://doi.
org/10.1007/s12325-019-00936-3.
17. J v M, Mrcsed JM. Is methoxyflurane a suitable battlefield analgesic? JR
Army Med Corps. 153(2):111–3. https://doi.org/10.1136/jramc-153-02-08.
18. Griffiths E. Efficacy and safety of methoxyflurane: managing trauma
associated pain in UK SAR helicopter paramedic practice. J Paramedic Pract.
2017;2;9(3):108-20.
19. Bijur PE, Kenny MK, Gallagher EJ. Intravenous morphine at 0.1mg/kg is not
effective for controlling severe acute pain in the majority of patients. Ann Emerg
Med. 2005;46(4):362–7. https://doi.org/10.1016/j.annemergmed.2005.03.010.
20. Porter KM, Siddiqui MK, Sharma I, Dickerson S, Eberhardt A. Management of
trauma pain in the emergency setting: low-dose methoxyflurane or nitrous
oxide? A systematic review and indirect treatment comparison. J Pain Res.
2018;11:11–21. https://doi.org/10.2147/JPR.S150600.
21. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P,
Stewart LA. Preferred reporting items for systematic review and meta-
analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1-9.
22. Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic
reviews of interventions . https://training.cochrane.org/handbook
23. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. BMJ (Online).
2009;339(7716):332–6. https://doi.org/10.1136/bmj.b2535.
24. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and
mobile app for systematic reviews. Syst Rev. 2016;5(1). https://doi.org/10.
1186/s13643-016-0384-4.
Eager et al. Systematic Reviews           (2021) 10:47 Page 5 of 6
25. Methoxyflurane | Drug | BNF content published by NICE. Accessed June 17,
2020. https://bnf.nice.org.uk/drug/methoxyflurane.html
26. Young T, Hopewell S. Methods for obtaining unpublished data.
Cochrane Database Syst Rev. 2011;11. https://doi.org/10.1002/14651858.
mr000027.pub2.
27. Abell B, Glasziou P, Hoffmann T. Reporting and replicating trials of exercise-
based cardiac rehabilitation: do we know what the researchers actually did?
Circ Cardiovasc Qual Outcomes. 2015;8(2):187–94. https://doi.org/10.1161/
CIRCOUTCOMES.114.001381.
28. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing
risk of bias in randomised trials. The BMJ. 2019;366. https://doi.org/10.
1136/bmj.l4898.
29. Review Manager Web (RevMan Web). Published online 2019. revman.
cochrane.org
30. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on
rating quality of evidence and strength of recommendations. BMJ. 2008;
336(7650):924–6. https://doi.org/10.1136/bmj.39489.470347.ad.
31. Campbell M, McKenzie JE, Sowden A, et al. Synthesis without meta-analysis
(SWiM) in systematic reviews: reporting guideline. The BMJ. 2020;368.
https://doi.org/10.1136/bmj.l6890.
32. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. BMJ. 1997;315:629–34.
33. Olsen MF, Bjerre E, Hansen MD, et al. Pain relief that matters to patients:
systematic review of empirical studies assessing the minimum clinically
important difference in acute pain. BMC Medicine. 2017;15(1):35. https://doi.
org/10.1186/s12916-016-0775-3.
34. Montassier E, Freund Y. Guidelines for letters to the editor
methoxyflurane may provide faster relief than suboptimal treatment,
but not better. Ann Emerg Med. 2020;75:550–1. https://doi.org/10.1016/j.
annemergmed.2019.12.007.
35. Grindlay J, Babl FE. Review article: efficacy and safety of methoxyflurane
analgesia in the emergency department and prehospital setting. Emerg
Med Australas. 2009;21(1):4–11. https://doi.org/10.1111/j.1742-6723.2009.
01153.x.
36. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and
research outcome. Cochrane Database Syst Rev. 2017;2:MR000033. https://
doi.org/10.1002/14651858.MR000033.pub3.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Eager et al. Systematic Reviews           (2021) 10:47 Page 6 of 6
